Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 558 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Nonalcoholic Fatty Liver Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Nonalcoholic Fatty Liver Disease and Atherosclerotic Risk in Children

NCT02383485
View directory record Official record
Conditions
Overweight and Obesity, Non-alcoholic Fatty Liver Disease
Interventions
Exercise, After-school program
Behavioral
Lead sponsor
Augusta University
Other
Eligibility
8 Years to 11 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Results available

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT04971785
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), PTM SEMA, PTM CILO/FIR
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
175
States / cities
Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 137 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Results available

The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis

NCT04134091
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
LPCN 1144 Formulation A, LPCN 1144 Formulation B, Placebo
Drug
Lead sponsor
Lipocine Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
19
States / cities
El Cajon, California • Murrieta, California • Rialto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 23, 2026, 8:19 AM EDT
Terminated Phase 2 Interventional Results available

A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

NCT04378010
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
EDP-305 1.5 mg, EDP-305 2 mg, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
68
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Results available

Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis

NCT03863574
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis
Interventions
Saroglitazar Magnesium 2mg, Saroglitazar Magnesium 4mg, Placebos
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Jackson, Mississippi • Germantown, Tennessee • Hermitage, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 23, 2026, 8:19 AM EDT
Withdrawn Not applicable Interventional

A Study to See if Low Level Laser Light Therapy (LLLT) Can Improve the Condition of Nonalcoholic Steatohepatitis (NASH)

NCT03163810
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Erchonia Verju Laser, Erchonia EVRL Laser
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Sep 23, 2026, 8:19 AM EDT
Terminated No phase listed Observational

A Study to Identify and Characterize LAL-D Patients in High-risk Populations

NCT02345421
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Sep 23, 2026, 8:19 AM EDT
Recruiting Phase 3 Interventional

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Efruxifermin, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
165
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 139 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 23, 2026, 8:19 AM EDT
Recruiting Phase 4 Interventional

Quantifying Hepatic Mitochondrial Fluxes in Humans

NCT05305287
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders
Interventions
Pioglitazone, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Results available

A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

NCT03400163
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
BMS-986036, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Sep 23, 2026, 8:19 AM EDT
Completed No phase listed Observational

Vitamin D Replacement in Nonalcoholic Fatty Liver Disease

NCT03084328
View directory record Official record
Conditions
Nonalcoholic Fatty Liver
Interventions
Vitamind D
Dietary Supplement
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
48 participants
Timeline
2012 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 2 Interventional

Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects

NCT04505436
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
HM15211, Placebo of HM15211
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
48
States / cities
Huntsville, Alabama • Chandler, Arizona • Chula Vista, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 23, 2026, 8:19 AM EDT
Terminated Phase 1Phase 2 Interventional

The Effect of Good Bacteria on Nonalcoholic Fatty Liver Disease in Diabetics

NCT00068094
View directory record Official record
Conditions
Fatty Liver, Hepatic Steatosis, Diabetes Mellitus, Liver Diseases
Interventions
Probiotic-containing powder
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Results available

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

NCT04321031
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis With Liver Fibrosis
Interventions
Placebo, PF-06865571, PF-05221304
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
184
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects

NCT03681457
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
LJN452
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
3
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 13, 2020 · Synced Sep 23, 2026, 8:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome

NCT02083367
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Nonalcoholic Steatohepatitis, Hepatitis C
Interventions
Not listed
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated May 24, 2015 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Results available

Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)

NCT06482112
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Liver Disease
Interventions
Efinopegdutide
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
36
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 23, 2026, 8:19 AM EDT
Recruiting Phase 3 Interventional

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions
Tirzepatide, Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
4,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
142
States / cities
Tuscaloosa, Alabama • Chandler, Arizona • Gilbert, Arizona + 123 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 23, 2026, 8:19 AM EDT
Completed No phase listed Observational

Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease (NAFLD)

NCT02363309
View directory record Official record
Conditions
Fatty Liver
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
21 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Results available

Study of INT-747 in Patients With Diabetes and Presumed NAFLD

NCT00501592
View directory record Official record
Conditions
Diabetes Mellitus, Type II, Fatty Liver
Interventions
INT-747, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Chula Vista, California • San Diego, California • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Sep 23, 2026, 8:19 AM EDT
Active, not recruiting No phase listed Observational

LITMUS Imaging Study

NCT05479721
View directory record Official record
Conditions
NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, Steatosis of Liver
Interventions
Not listed
Lead sponsor
University of Oxford
Other
Eligibility
18 Years to 100 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 23, 2026, 8:19 AM EDT
Terminated No phase listed Observational

Study Evaluating Metabolic Syndrome in Subjects Undergoing Gastric Bypass Bariatric Syndrome

NCT00283374
View directory record Official record
Conditions
Morbid Obesity, Metabolic Disease
Interventions
Laparoscopic Roux-en-Y Gastric Bypass
Procedure
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
10
States / cities
Irvine, California • Orange, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 17, 2006 · Synced Sep 23, 2026, 8:19 AM EDT
Completed Not applicable Interventional

Effects of Alanine in Patients With Nonalcoholic Steatohepatitis

NCT00586885
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
L-alanine
Drug
Lead sponsor
Keith D Lindor, M.D.
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Sep 23, 2026, 8:19 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

NCT03053050
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
SEL, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
124
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 95 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2020 · Synced Sep 23, 2026, 8:19 AM EDT